Century Therapeutics

Philadelphia, PA · Founded 2019 · CIK 0001850119 · Biotech · Private

Allogeneic, iPSC-derived NK and T cell therapies for cancer and immune diseases

centurytx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$160M
1 Form D · Mar 2021
67 months since last filing
Contracts
—
No federal contracts on record
Patents
40
3 granted · 37 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$160,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3303Stramsen Biotech, Inc.—$5.0M
3304Syncromune, Inc.—$56M
3305TuHURA Biosciences, Inc.—$21M
3306Century Therapeutics—$160M
3307SilverCeuticals Inc.—$5.0M
3308ORF Biologics, Inc.—$2.5M
3309Blue Marlin Data Fund, LLC—$16M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Toshikazu BanDirector
  • Cynthia ButittaDirector
  • Douglas CarrExecutive Officer
  • Eli CasdinDirector
  • Juergen EckhardtDirector
  • Osvaldo Flores, Ph.D.Director · Executive Officer
  • Joseph JimenezDirector
  • Carlo RizzutoDirector

Patents

USPTO · 3 granted of 40
  • Cells Expressing Antigen- & Sequence-specific T-cell Receptors (tcrs) And Methods Of Making The Same Using Enforced Tcr Gene Rearrangementapplication
  • Immunoeffector Cells Derived From Induced Pluripotent Stem Cells Genetically Engineered With Membrane Bound IL12 And Uses Thereofapplication
  • Cells Engineered With An Hla-e And Hla-g Transgeneapplication
  • Artificial Cell Death Polypeptide For Chimeric Antigen Receptor And Uses Thereofgranted
  • Genetically Engineered Cells Having ANTI-CD133 / Anti-egfr Chimeric Antigen Receptors, And Uses Thereofapplication
  • Genetically Engineered Cells Having ANTI-CD19 / ANTI-CD22 Chimeric Antigen Receptors, And Uses Thereofapplication
  • Compositions and Methods for Generating Gamma-Delta T Cells from Induced Pluripotent Stem Cellsapplication
  • Artificial Cell Death Polypeptide For Chimeric Antigen Receptor And Uses Thereofapplication
  • Chimeric Antigen Receptor System With Adaptable Receptor Specificityapplication
  • Chimeric Antigen Receptor System With Adaptable Receptor Specificitygranted
  • Methods For Controlled Activation And/or Expansion Of Genetically Engineered Cells Using Polyethylene Glycol (peg) Receptorsapplication
  • Artificial Cell Death Polypeptide For Chimeric Antigen Receptor And Uses Thereofgranted

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.